The research team, led by Zhilan Zhang and Ping Zhou of Xiangya Hospital of Central South University together with colleagues at Central South University Xiangya School of Medicine Affiliated Haikou Hospital, began by examining human hepatocellular carcinoma samples. They found that several immune-related molecules were prominently expressed in tumor tissue: LAG-3, an inhibitory receptor expressed on exhausted T cells; CXCL10, a chemokine secreted in response to inflammatory signals; CXCR3, the receptor on T cells that binds CXCL10; and CD8, the defining marker of cytotoxic T lymphocytes. This molecular signature hinted that the CXCL10/CXCR3 axis, a well-known trafficking pathway that guides activated T cells into inflamed tissue, was active in the liver tumor microenvironment, and that LAG-3-mediated suppression might be restraining the very T cells the pathway was drawing in.

To test the functional significance of these observations, the investigators turned to hepatocellular carcinoma-bearing mice. When the animals received microwave ablation, a technique that uses electromagnetic energy to generate lethal heat within tumor tissue, the researchers observed a striking change in the tumor-infiltrating lymphocyte population: LAG-3 expression rose on subsets of the infiltrating T cells. In other words, ablation did not merely shrink the tumor; it reshaped the immune landscape, drawing lymphocytes into the remaining tumor while simultaneously increasing the prevalence of the inhibitory checkpoint that can render those lymphocytes dysfunctional. This observation provided a mechanistic explanation for why local ablation alone often fails to prevent recurrence and why pairing it with checkpoint blockade could be advantageous.

LAG-3, or lymphocyte-activation gene 3, has attracted intense interest in oncology because it regulates T cell exhaustion through pathways that are distinct from those of the better-known checkpoint molecules PD-1 and CTLA-4. By binding its ligands and transmitting inhibitory signals, LAG-3 dampens the proliferative and cytotoxic capacity of T cells. Blocking LAG-3 with antibodies releases this brake, and several anti-LAG-3 agents are already in clinical development for solid tumors and hematologic malignancies. The new study asked a specific and clinically important question: does LAG-3 blockade complement microwave ablation in hepatocellular carcinoma, and if so, through what molecular circuitry?

The answer, according to the mouse experiments, is a clear yes. Compared with either microwave ablation or anti-LAG-3 therapy alone, the combined treatment produced a synergistic anti-tumor effect. Mice receiving both interventions survived significantly longer and showed markedly inhibited tumor growth. Beyond the gross measures of tumor burden, the combination also remodeled the tumor immune microenvironment in ways that favored immune attack: tumor-infiltrating lymphocytes increased in number, serum levels of CXCL10 rose, the population of CXCR3-positive CD8+ T cells expanded, and the cytotoxic activity of CD8+ T cells was enhanced. The convergence of increased chemokine production with greater numbers of chemokine-receptor-bearing killer cells suggested that the CXCL10/CXCR3 axis was the engine driving the therapeutic synergy.

To confirm that the chemokine axis was genuinely required rather than merely correlated, the researchers performed two decisive loss-of-function experiments. First, they blocked CXCL10 in mice receiving the combined therapy. Neutralizing the chemokine weakened CD8+ T cell function, demonstrating that the chemokine signal is necessary for the enhanced cytotoxic response. Second, they depleted or blocked CD8+ T cells themselves under the combined regimen. This maneuver promoted tumor growth and impaired the anti-tumor benefit, establishing CD8+ T cells as the essential cellular mediators of the combination effect. Together, the two experiments trace the causal chain: microwave ablation and LAG-3 blockade act together to elevate CXCL10, CXCL10 engages CXCR3 on CD8+ T cells to recruit and activate them, and activated CD8+ T cells execute the tumor killing.

The mechanistic picture is biologically plausible and fits with established immunology. Thermal injury from ablation is known to release tumor antigens and danger signals that provoke local inflammation, and inflammatory cytokines such as interferon-gamma induce CXCL10 production in stromal and immune cells. At the same time, the influx of newly activated T cells into this inflammatory environment creates a larger pool of cells vulnerable to LAG-3-mediated inhibition, which likely explains why LAG-3 expression climbed on tumor-infiltrating lymphocytes after ablation in the study. Removing that constraint with an anti-LAG-3 antibody allows the newly recruited CD8+ T cells to proliferate, produce cytotoxic molecules such as granzyme B, and sustain their attack on residual tumor cells, including microscopic deposits that ablation cannot physically reach.

Hepatocellular carcinoma remains one of the most lethal and rapidly increasing cancers worldwide, frequently diagnosed at an advanced stage when curative resection or transplantation is no longer feasible. Immune checkpoint inhibitors have transformed the treatment landscape in recent years, but only a fraction of patients respond durably, and resistance remains a central clinical problem. Locoregional therapies such as microwave ablation are standard of care for early-stage disease, yet recurrence is common. A regimen that combines the antigen-releasing and inflammation-generating effects of ablation with checkpoint blockade that preserves T cell function could address both limitations simultaneously, converting an otherwise localized treatment into an in situ cancer vaccine while ensuring the recruited immune cells retain full killing capacity.

The authors emphasize that the therapeutic potential of combining microwave ablation with LAG-3 blockade had already been demonstrated in various cancers, but its specific efficacy and molecular mechanisms in hepatocellular carcinoma had remained unclear. By identifying the CXCL10/CXCR3 pathway as the mechanistic bridge, the study fills that gap and provides biomarkers that could be used to monitor or stratify patients. Serum CXCL10 levels, the frequency of CXCR3-positive CD8+ T cells, and LAG-3 expression on tumor-infiltrating lymphocytes are all measurable in clinical settings and could serve as pharmacodynamic indicators of whether the combination is engaging its intended immune circuitry in human trials.

The study was supported by the Natural Science Foundation of Hainan Province, and all animal procedures were approved by the Animal Care and Ethical Standards Committee of Central South University Xiangya School of Medicine Affiliated Haikou Hospital. The authors declared no competing financial interests. As with any preclinical finding, important caveats apply before the results can inform patient care. Mouse models of hepatocellular carcinoma do not fully recapitulate the immunosuppressed, cirrhotic, hepatitis- or metabolically driven liver environment in which human tumors arise, and the dosing, timing, and sequencing of ablation relative to checkpoint blockade will require careful optimization in clinical studies. Nevertheless, the identification of a defined chemokine-dependent mechanism gives the field a concrete target around which to design combination trials, and it reinforces a growing consensus in immuno-oncology: the most effective treatments will be those that simultaneously generate the raw materials of an immune response and remove the brakes that prevent that response from succeeding.

Autologous TIL therapy is an immunotherapeutic approach that leverages the patient’s own immune system to combat malignant cells. TILs are lymphocytes naturally present within a tumor, harboring the innate capability to recognize cancer-specific antigens. The therapeutic process involves surgically extracting these lymphocytes from tumor biopsies, expanding them ex vivo to quantities often reaching into the hundreds of millions, and infusing them back into the patient. This infusion aims to augment the immune response by saturating the body with highly active, tumor-specific lymphocytes capable of targeting and dismantling cancer cells more effectively than the patient’s unassisted immune system.

The impetus for this trial stems from earlier observational studies indicating that higher levels of TILs within tumors correlate with improved disease-free survival rates among HNSCC patients. This established an immunological rationale for enhancing TIL presence therapeutically, particularly within the context of recurrent or metastatic disease where conventional therapies—such as chemotherapy, radiation, and surgery—have often failed. The phase 2 trial enrolled 53 patients categorized into four distinct treatment arms, which allowed for a comparative assessment of various TIL formulations. These included non-cryopreserved TILs, cryopreserved lifileucel—an FDA-approved T-cell therapy previously validated in metastatic melanoma—non-cryopreserved lifileucel, and a cryopreserved TIL therapy enriched for PD-1 positive cells. PD-1 is an immune checkpoint receptor commonly expressed on T cells, acting as a marker for tumor-reactive lymphocytes.

Participants in the study predominantly consisted of males, with a median age of 57 years, suffering from late-stage metastatic HNSCC. The median duration of treatment exposure was approximately 17.9 months, and the median response to therapy lasted 7.6 months, though some patients experienced disease stabilization for nearly two years. Impressively, 64% of patients across the cohorts achieved stabilization of cancer progression—a benchmark that, until this study, had been elusive for this clinical population. The median overall survival was reported to be 9.5 months, a figure that notably surpasses existing outcomes for similar patient groups who have exhausted standard care options.

Side effect profiles were consistent with expectations for TIL-based therapies, which can prompt systemic inflammatory responses due to lymphocyte activation. The most prevalent non-hematologic adverse events included chills, experienced in 60% of patients, hypotension in 53%, and fever in 47%. Hematologic toxicities manifested as thrombocytopenia and anemia, with incidences of 74% and 53%, respectively. These side effects, while notable, were generally manageable with supportive care. The trial’s safety data reinforce the feasibility of administering TIL therapies to this fragile cohort without incurring unacceptable toxicity.

Robert L. Ferris, MD, PhD, who led the investigation while at UPMC Hillman Cancer Center and subsequently analyzed the findings as executive director at UNC Lineberger, underscored the significance of the outcomes. Ferris highlighted that these patients usually have limited life expectancy due to aggressive disease and prior treatment failures. The approximate nine-month extension in survival attributable to TIL therapy represents a meaningful clinical breakthrough, underscoring the importance of immunotherapeutic strategies in refractory solid tumors.

Despite these encouraging results, Ferris and colleagues acknowledged challenges inherent to the therapy’s broader applicability. The relatively small patient populations in each treatment arm limited the ability to perform direct statistical comparisons, emphasizing the necessity for larger, randomized controlled trials to comprehensively ascertain efficacy. Furthermore, questions remain regarding the optimization of TIL manufacturing—whether fresh or cryopreserved cells yield superior clinical outcomes—as well as the identification of synergistic combination regimens that could potentiate anti-tumor effects while mitigating immune evasion.

Of particular interest is the enrichment for PD-1 positive TILs, leveraging the understanding that these cells bear markers of prior tumor engagement and potential exhaustion. Modulating this population through adjunctive therapies, such as immune checkpoint inhibitors, might amplify the therapeutic durability of TIL infusions. Exploring these combinations could usher in a new paradigm in HNSCC treatment, providing not just disease stabilization but meaningful regression and long-term remission.

Head and neck squamous cell carcinoma remains a significant clinical challenge worldwide, accounting for approximately 3.6% of all new cancers in the United States, with nearly 60,000 diagnoses anticipated in 2025 alone. The notoriously aggressive nature of metastatic HNSCC, combined with frequent resistance to chemo- and radiotherapies, underscores the urgency of novel immunotherapies. The present study’s findings affirm the potential of individualized cell-based immunotherapies to fill this critical therapeutic void.

Underlying the trial’s success was a collaboration with Iovance Biotherapeutics, the manufacturer of lifileucel, ensuring access to cutting-edge cell manufacturing technologies. Lifileucel’s prior approval for metastatic melanoma provided a precedent for its adaptation in HNSCC, and the current findings could expand the therapeutic indications for this biologic agent. Moving forward, the results pave the way for subsequent large-scale studies designed to evaluate TIL therapy head-to-head against current standards of care, possibly reshaping treatment algorithms within oncology.

As the field of cancer immunotherapy evolves, the implications of TIL therapy extend beyond head and neck cancers. Enhancing the precision of adoptive T-cell therapies, optimizing cell culture conditions, and refining patient selection criteria hold promise for improving outcomes across various malignancies. This trial stands as a landmark step, illuminating the path toward harnessing the patient’s own immune system to tackle some of the most intractable cancers known to medicine.

In summary, the phase 2 clinical trial of autologous TIL therapy in recurrent and metastatic head and neck squamous cell carcinoma offers a compelling narrative of hope and scientific rigor. With the therapy demonstrating a tangible survival benefit and manageable safety profile, the findings invigorate the quest for personalized immunotherapies. Future research is expected to focus on combination modalities, refined manufacturing processes, and randomized trials that will ultimately define the clinical utility of TIL therapy in oncology practice.

Subject of Research: People

Article Title: Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

News Publication Date: 24-Aug-2025

Web References:
https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-011633

Image Credits: UNC Lineberger Comprehensive Cancer Center

Keywords: Cancer, Immunology, Cancer immunology, Immunotherapy, Head and neck cancer, Lymphocytes